|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0012854,
umls-concept:C0020964,
umls-concept:C0042196,
umls-concept:C0085358,
umls-concept:C0205263,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1550147,
umls-concept:C1706438,
umls-concept:C2349975,
umls-concept:C2698600
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2008-5-16
|
|
pubmed:abstractText |
Because the combination of multiple modalities for cancer treatment is more likely to generate more potent therapeutic effects for the control of cancer, we have explored the combination of chemotherapy using cisplatin, which is routinely used in chemotherapy for advanced cervical cancer, with immunotherapy using DNA vaccines encoding calreticulin (CRT) linked to human papillomavirus type 16 E7 antigen (CRT/E7) in a preclinical model.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-10584920,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-10706121,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-10772987,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-10837079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-11062756,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-11325840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-11544272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-12669466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-14564514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-14985791,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-15474971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-16166275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17200373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17234792,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17266502,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17408372,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17576157,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17617589,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17931752,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-17981543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-3909096,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-8548765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18483387-9000640
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Calreticulin,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Papillomavirus E7 Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, DNA,
http://linkedlifedata.com/resource/pubmed/chemical/oncogene protein E7, Human...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AlvarezRonald DRD,
pubmed-author:ChuangChi-MuCM,
pubmed-author:HeLiangmeiL,
pubmed-author:HuhWarner KWK,
pubmed-author:HungChien-FuCF,
pubmed-author:KimDaejinD,
pubmed-author:LinCheng-TaoCT,
pubmed-author:MonieArchanaA,
pubmed-author:TrimbleCorneliaC,
pubmed-author:TsaiYa-CheaYC,
pubmed-author:TsengChih-WenCW,
pubmed-author:UeoKK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3185-92
|
|
pubmed:dateRevised |
2011-7-27
|
|
pubmed:meshHeading |
pubmed-meshheading:18483387-Animals,
pubmed-meshheading:18483387-Biolistics,
pubmed-meshheading:18483387-CD8-Positive T-Lymphocytes,
pubmed-meshheading:18483387-Calreticulin,
pubmed-meshheading:18483387-Cancer Vaccines,
pubmed-meshheading:18483387-Cisplatin,
pubmed-meshheading:18483387-Combined Modality Therapy,
pubmed-meshheading:18483387-Cytotoxicity, Immunologic,
pubmed-meshheading:18483387-Female,
pubmed-meshheading:18483387-Flow Cytometry,
pubmed-meshheading:18483387-Histocompatibility Antigens Class I,
pubmed-meshheading:18483387-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:18483387-Mice,
pubmed-meshheading:18483387-Neoplasms, Experimental,
pubmed-meshheading:18483387-Oncogene Proteins, Viral,
pubmed-meshheading:18483387-Papillomavirus E7 Proteins,
pubmed-meshheading:18483387-Polymerase Chain Reaction,
pubmed-meshheading:18483387-Vaccines, DNA
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
|
|
pubmed:affiliation |
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
